PureCycle Technologies 주식 (NASDAQ: PCT)

에 대한 최신 뉴스 PureCycle Technologies (NASDAQ:PCT) 주식

PureCycle Technologies

PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.

Mid Cap

News

Movers

Trading Ideas

$BTC

IBRX

IONQ

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies Inc

PACT GROUP HLDGS UNSP/ADR by Pact Group Holdings Ltd

Pact Group Holdings Ltd

PCTEL Inc

PCT Ltd

PICTON PPTY INCOME LTD by Picton Ppty Income Ltd.

Paylocity Holding Corporation - Common Stock

Paylocity Holding Corp

BRAVERN VENTURES LTD by Bravern Ventures Ltd

Bravern Ventures Ltd

Barclays analyst Christine Cho maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Underperform and lowers the price target from $17 to $7.

Price Target

Analyst Ratings

SEDG

Barclays Maintains Underperform on SolarEdge Technologies, Lowers Price Target to $7

TD Cowen analyst Krish Sankar maintains Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) with a Hold and raises the price target from $45 to $50.

KLIC

TD Cowen Maintains Hold on Kulicke & Soffa Indus, Raises Price Target to $50

WIIM

Cue Biopharma shares are trading lower. The company reported Q3 financial results.

Jefferies analyst Corey Tarlowe maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and lowers the price target from $110 to $90.

Jefferies Maintains Buy on Dollar Gen, Lowers Price Target to $90

On Thursday, Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) announced the termination of its merger agreement with Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), citing <a target="_blank" href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles" rel="noreferrer noopener">uncertainty in the legal process.</a>
Following the termination of the merger agreement, Tapestry said it will redeem $6.1 billion in senior notes tied to the acquisition, paying 101% of their principal amount plus accrued interest, as per the Special Mandatory Redemption clause. Tapestry will also reimburse Capri $45 million for transaction-related expenses.
Here are the analysts&#8217; takes <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41550527/why-capri-holdings-stock-is-falling-today" rel="noreferrer noopener">on the&nbsp;termination news</a>:
Telsey Advisory Group: Analyst Dana Telsey maintained the Market Perform rating on Capri Holdings, lowering <a target="_blank" href="https://www.benzinga.com/quote/CPRI/analyst-ratings" rel="noreferrer noopener">the price forecast to $23 from $26</a>. Considering the string of disappointing results over the past several quarters, the analyst trimmed the price forecast.
Per the analyst, the company saw some initial successes, but the campaigns didn&#8217;t connect well with its core customers. It raised price points too quickly. Additionally, the brand reduced its signature products and introduced too much fashion, leading to deeper promotions to drive sales.
However, for Tapestry, the analyst raised the price forecast to $67 from $58, <a target="_blank" href="https://www.benzinga.com/quote/TPR/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>. Telsey is optimistic about earnings growth from the new buyback authorization and the company&#8217;s strong balance sheet.
The analyst sees no near-term acquisitions while focusing on improving Kate&#8217;s performance.
Meanwhile, the Coach brand remains resilient, with a 2% increase in constant currency last quarter, the analyst writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say" rel="noreferrer noopener">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders Say</a>
Guggenheim: Analyst Robert Drbul maintained a Neutral rating on Capri Holdings, citing the company&#8217;s deteriorating results over the past few years. The analyst pointed out &#8220;multiple missteps&#8221; by the company, including focus on younger consumers, rapid price increases, and reduced promotions.
Drbul also criticized the reduction of signature styles and overemphasis on &#8220;fashion&#8221; at Michael Kors. At Versace, the shift toward luxury/quality alienated the aspirational consumer by removing statement items. The analyst lowered FY25/FY26 EPS estimates to $1.50/$2.00, down from $1.85/$2.10. Per Drbul, Capri&#8217;s current low valuation could attract offers.
Drbul reiterated the Buy rating on Tapestry, raising the price forecast to $70 from $60. The analyst notes Tapestry will focus on strengthening Coach and Kate Spade, not pursuing acquisitions for now. With the Capri merger behind, Drbul sees value in Tapestry&#8217;s current portfolio.
The company is expected to benefit from pricing power in FY25 and may reach a 19% operating margin, with long-term potential to return to pre-COVID margins, driven by DTC growth and expansion in Asia, Drbul writes.
JP Morgan: Analyst Matthew R. Boss reiterated the Neutral rating on Capri Holdings, with a price forecast of $15. The analyst projects FY25 EPS of $1.44, 17% below consensus, with a 14% year over year revenue decline and a 45bps gross margin contraction.&nbsp;
For the second half of 2025, the analyst projects revenues to be down 13% (an improvement from the first half&#8217;s -15%), gross margins to decrease by 10bps year over year (compared to the first half&#8217;s -80bps).
Capri Holdings&#8217; shift to a higher direct-to-consumer sales mix has boosted full-price selling, but also increased operating expenses, Boss writes. The analyst warns that with limited opportunities to cut SG&amp;A costs, this could be challenging amid a slowing top-line growth.
Price Action: CPRI shares are trading higher by 1.80% to $20.89 at last check Friday, while TPR shares are trading lower by 0.98% to $57.26.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft" target="_blank" rel="noreferrer noopener">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></li>
</ul>

Analyst Color

Equities

Reiteration

Markets

General

CPRI

Tapestry Poised For Solid Growth After Capri Merger Termination, Analysts Cite Struggles And Missteps At Capri

TD Cowen analyst Krish Sankar maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $250 to $230.

AMAT

TD Cowen Maintains Buy on Applied Mat, Lowers Price Target to $230

Whales with a lot of money to spend have taken a noticeably bullish stance on Morgan Stanley.
Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 23 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $332,437 and 16, calls, for a total amount of $1,219,604.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $185.0 for Morgan Stanley during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Morgan Stanley's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Morgan Stanley's significant trades, within a strike price range of $95.0 to $185.0, over the past month.
<h3>Morgan Stanley Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696369_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$140.00</td>
<td>$340.0K</td>
<td>3.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.85</td>
<td>$5.15</td>
<td>$6.85</td>
<td>$185.00</td>
<td>$136.8K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$125.2K</td>
<td>6.4K</td>
<td>293</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.75</td>
<td>$140.00</td>
<td>$103.2K</td>
<td>224</td>
<td>75</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$115.00</td>
<td>$85.0K</td>
<td>7.3K</td>
<td>47</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
In light of the recent options history for Morgan Stanley, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Morgan Stanley Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,092,834, with MS's price up by 0.76%, positioned at $133.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Morgan Stanley</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $128.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Morgan Stanley, which currently sits at a price target of $121. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Underweight rating for Morgan Stanley, targeting a price of $107. 
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $142. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Morgan Stanley, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Morgan Stanley: Analyzing the Surge in Options Activity

Investors with significant funds have taken a bullish position in Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in LDOS usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Leidos Holdings. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 50% bearish. Of all the options we discovered, 7 are puts, valued at $974,530, and there was a single call, worth $29,500.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $170.0 for Leidos Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Leidos Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Leidos Holdings's significant trades, within a strike price range of $130.0 to $170.0, over the past month.
<h3>Leidos Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696364_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$4.8</td>
<td>$5.4</td>
<td>$155.00</td>
<td>$346.1K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$8.4</td>
<td>$7.0</td>
<td>$8.4</td>
<td>$130.00</td>
<td>$168.0K</td>
<td>1.5K</td>
<td>77</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.7</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$165.00</td>
<td>$148.7K</td>
<td>127</td>
<td>133</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$155.00</td>
<td>$111.9K</td>
<td>0</td>
<td>232</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$5.8</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$96.5K</td>
<td>202</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Leidos Holdings</h3>
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in three reportable segments; Defense Solutions, Civil, and Health. Defense Solutions provides technologically latest services, solutions, and products to a broad customer base. It generates key revenue from Defense Solutions.
After a thorough review of the options trading surrounding Leidos Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Leidos Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,765,461, the LDOS's price is down by -5.9%, now at $158.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Leidos Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $212.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Leidos Holdings, which currently sits at a price target of $200. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Leidos Holdings with a target price of $210. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Leidos Holdings, which currently sits at a price target of $230. 
&#x2A; An analyst from Baird persists with their Outperform rating on Leidos Holdings, maintaining a target price of $218. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Leidos Holdings, maintaining a target price of $205. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Leidos Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

LDOS

Unpacking the Latest Options Trading Trends in Leidos Holdings

High-rolling investors have positioned themselves bullish on NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for NextNav. This is not a typical pattern.
The sentiment among these major traders is split, with 69% bullish and 23% bearish. Among all the options we identified, there was one put, amounting to $105,000, and 12 calls, totaling $504,800.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $17.0 for NextNav over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NextNav's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextNav's whale activity within a strike price range from $3.0 to $17.0 in the last 30 days. 
<h3>NextNav Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696359_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.4</td>
<td>$3.00</td>
<td>$125.4K</td>
<td>2.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>NN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.75</td>
<td>$15.00</td>
<td>$105.0K</td>
<td>26</td>
<td align="right">600</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$17.00</td>
<td>$46.9K</td>
<td>566</td>
<td align="right">70</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.9</td>
<td>$6.7</td>
<td>$7.84</td>
<td>$15.00</td>
<td>$39.4K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$12.00</td>
<td>$39.3K</td>
<td>693</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About NextNav</h3>
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation and Timing services in the absence of GPS.
In light of the recent options history for NextNav, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of NextNav</h3>
<ul>
<li>Trading volume stands at 568,994, with NN's price up by 0.85%, positioned at $14.27.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 117 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NextNav options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in NextNav

TD Cowen analyst Lance Vitanza maintains Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) with a Hold and lowers the price target from $20 to $16.

INSG

TD Cowen Maintains Hold on Inseego, Lowers Price Target to $16

Jefferies analyst Corey Tarlowe maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $95 to $105.

Jefferies Maintains Buy on BJ's Wholesale Club, Raises Price Target to $105

TD Cowen analyst Bryan Bergin maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $230 to $240.

GLOB

TD Cowen Maintains Buy on Globant, Raises Price Target to $240

Jefferies analyst Corey Tarlowe maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

Jefferies Maintains Buy on Walmart, Raises Price Target to $100

ABAT

American Battery Technology shares are trading lower. The company reported Q1 financial results.

TD Cowen analyst Doug Creutz maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Hold and raises the price target from $108 to $123.

TD Cowen Maintains Hold on Walt Disney, Raises Price Target to $123

Jefferies analyst Samad Samana maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $230 to $215.

NICE

Jefferies Maintains Buy on NICE, Lowers Price Target to $215

Goatseus Maximus (CRYPTO: GOAT) has seen impressive gains, climbing 35.3% over the past week. The rally places the AI meme coin at the forefront of the meme coin market, with traders <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41432283/move-over-dogecoin-shiba-inu-ai-meme-coin-goat-prints-over-3-million-in-profit-for-whale-t">anticipating further upside</a>. 
What Happened: The gain pushed its valuation to $1 billion placing it in the top ten of the meme coin board.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Goatseus Maximus (CRYPTO: GOAT)</td>
<td>&nbsp;$1.02</td>
<td>$1 Billion</td>
<td>&nbsp;+10.7%</td>
<td>&nbsp;+33%</td>
</tr>
<tr>
<td>Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td> $1.67</td>
<td>$1.6 Billion</td>
<td>&nbsp;-5.9%</td>
<td>&nbsp;+9.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With prices picking up steam, crypto trader Lucky <a href="https://x.com/LuckyXBT__/status/1857396228939518186">sees</a> GOAT price action quite similar to painful Popcat price action before its own "bull run."
Crypto trader Aylo predicts a bullish trend for the meme coin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Clear skies ahead for <a href="https://twitter.com/search?q=%24GOAT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOAT</a> Time to accelerate. <a href="https://t.co/dxX2iJi3FT">pic.twitter.com/dxX2iJi3FT</a>
&mdash; Aylo (@alpha_pls) <a href="https://twitter.com/alpha_pls/status/1857432408414364014?ref_src=twsrc%5Etfw">November 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1857424121669324907">sees</a> GOAT finally getting the breakout, saying the AI meme coin is showing resilience, with dips being quickly bought up, signaling strong support.
A breakout is <a href="https://x.com/DaanCrypto/status/1856996799669530793">anticipated</a> due to its bullish chart pattern. As a leader in the AI meme coin meta, GOAT still lacks a Binance spot listing, but such a development could further boost its momentum.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41917072/dogecoin-is-the-best-trump-proxy-industry-expert-claims">Dogecoin Is The &#8216;Best Trump Proxy,&#8217; Industry Expert Claims</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$POPCAT

AI Meme Coin GOAT Joins $1 Billion Club—Can It Target The Likes Of Dogecoin, Shiba Inu?

<a href="https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad">https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad</a>
Microsoft has been turning its OpenAI deal into a big business. Earlier this year, much of its Azure OpenAI offering, which provides access to OpenAI's language models, was contingent on a single big spender: TikTok. But I've now seen a recent list of its top customers, and it's clear that Microsoft has managed to diversify the business with a selection of major clients spending more than $1 million per month on Azure OpenAI services.
The software giant has a running list of what it considers its top 10 customers for Azure OpenAI, and I'm told Adobe and Meta both spent more than $1 million on Microsoft's AI services in September alone to make the top 10 customer list. Both Adobe and Meta are primarily using Microsoft's provisioned output for access to OpenAI models, which provides dedicated model processing capacity rather than Microsoft's token-based offerings for text and image generation.
Meta and Adobe's use of Azure OpenAI still falls far behind TikTok owner ByteDance's, though. The Information reported earlier this year that TikTok was <a href="https://www.theverge.com/2024/7/31/24210667/microsoft-tiktok-ai-openai-customer">paying Microsoft almost $20 million</a> per month to access OpenAI's models, making up nearly a quarter of the revenue generated by Azure OpenAI at the time. ByteDance's spending on Azure OpenAI is now less than 15 percent of Microsoft's Azure OpenAI business, thanks in part to a more diverse amount of customer spending on Microsoft's AI services and ByteDance spending less.
 &nbsp;

ADBE

MSFT

Reported Earlier, 'Microsoft's Top AI Customers Include Adobe And Meta/ TikTok Is Still Microsoft's Top Azure OpenAI Customer, Though' - The Verge

TD Cowen analyst Bryan Bergin maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Buy and raises the price target from $533 to $567.

TD Cowen Maintains Buy on Mastercard, Raises Price Target to $567

On Friday, Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012383/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-elebsiran-combina" rel="noreferrer noopener">chronic hepatitis B</a>.
Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV).
The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39192084/why-is-infectious-disease-focused-vir-biotechnology-stock-trading-higher-on-wednesday" rel="noreferrer noopener">Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?</a>
Participants in the trial received tobevibart and elebsiran alone (doublet regimen) or in combination with PEG-IFNα (triplet regimen).
The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (&lt;1000 IU/mL) in both combination regimens.
The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39% (7/18) and 46% (5/11) of participants with baseline HBsAg&lt;1,000 IU/mL, respectively.
The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at the end of treatment was 16% (8/51) for the doublet and 22% (6/27) for the triplet regimen.
The doublet regimen resulted in 50% (4/8) of participants achieving HBsAg loss and anti-HBs seroconversion.
All participants with HBsAg loss at the end of treatment who received the triplet regimen achieved anti-HBs seroconversion (100%, 6/6).
Participants with HBsAg seroclearance at the end of treatment who meet eligibility criteria will discontinue treatment. A functional cure assessment will occur 24 weeks after treatment discontinuation.
Mark Eisner, Executive Vice President and Chief Medical Officer, Vir Biotechnology, said, &#8220;We are encouraged by these results and eagerly anticipate the functional cure data in 2025, as it will be decisive for the next steps of clinical development.&#8221;
Price Action: VIR stock is down 7.50% at $7.99 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012040/bristol-myers-faces-renewed-67-billion-lawsuit-over-drug-approval-delays-amid-resolved-trustee-issue" target="_blank" rel="noreferrer noopener">Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue</a></li>
</ul>

Biotech

Health Care

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

PureCycle Technologies ( ($PCT) ) has shared an announcement. PureCycle Technologies is making significant strides in plastic recycling, particular...

PureCycle Technologies Advances in Plastic Recycling

PureCycle Technologies GAAP EPS of -$0.29

Purecycle Technologies Inc ( ($PCT) ) has released its Q3 earnings. Here is a breakdown of the information Purecycle Technologies Inc presented to ...

PureCycle Technologies Advances in Recycling Innovations

TD Cowen analyst Jeff Osborne maintained a Buy rating on PureCycle Technologies (PCT – Research Report) today and set a price target of $10.00. The...

TD Cowen Sticks to Its Buy Rating for PureCycle Technologies (PCT)

PureCycle Technologies, Inc. 2024 Q3 - Results - Earnings Call Presentation

PureCycle Technologies, Inc. (PCT) Q3 2024 Earnings Conference Call Transcript

In a report released today, Brian Butler from Stifel Nicolaus reiterated a Buy rating on PureCycle Technologies (PCT – Research Report), with a pri...

Stifel Nicolaus Remains a Buy on PureCycle Technologies (PCT)

Stifel analyst Michael Hoffman raised the firm's price target on PureCycle Technologies (PCT) to $15 from $8 and keeps a Buy rating on the shares. ...

PureCycle Technologies price target raised to $15 from $8 at Stifel

Craig-Hallum analyst Eric Stine assigned a Hold rating to the stock today. The company's shares closed yesterday at $11.79. According to TipRanks, ...

PureCycle Technologies (PCT) Gets a Hold from Craig-Hallum

Unusual total active option classes on open include: Nasdaq 100 Micro Index (.XND), MindMed (MNMD), Direxion Daily S&P Bear (SPXS), Marqeta (MQ), A...

Unusually active option classes on open November 15th

AAOI

CHPT

MNMD

PCTTU

PCTTW

ULTA

Press Releases

PureCycle Provides Update on Ironton Purification Facility

Events

PureCycle to Participate in Stifel's 2024 Cross Sector Insight Conference

PureCycle to Receive Expanded FDA No Objection Letter for PureFive(TM) Resin Use in Cosmetics, Personal Care and Food Applications

Rise in Construction Activities Worldwide Generating Demand and Growth Opportunities for Metal Recycling Companies

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of PureCycle Technologies, Inc. - PCT

PureCycle Provides Second Quarter 2024 Update

PureCycle Announces Financing Transaction and Ironton Production Update

PureCycle Processes One Million Pounds in a Week at Ironton Facility

PureCycle Schedules Third Quarter 2024 Corporate Update

PureCycle Provides Third Quarter 2024 Corporate Update

GWAV

SRCL

STLD

AdvanSix

Braskem

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

CN Energy Group Inc. - Class A Ordinary Shares

CN Energy Group

Crown Electrokinetics Corp. - Common Stock

Crown ElectroKinetics

Gulf Resources

Hawkins

Koppers Hldgs

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Mat

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical

Stifel

Cantor Fitzgerald

Craig-Hallum

TD Cowen

Roth MKM

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주식은 회사가 재발성 <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-세포 비호지킨 림프종</a>에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.
2. 스트라이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>)의 주식은 회사가 1분기 실적이 예상보다 좋게 나타났고, 2025 회계연도 및 2분기 <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">매출 가이던스도 예상치를 상회</a>했다고 발표한 후 41.43% 급등했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
3. 퓨어사이클 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)의 <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">주식은 32.21% 상승</a>했다.
4. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주식은 지난주에 31.68% 상승했다. 이 주식은 다가오는 미국 선거를 앞두고 변동성을 보였다.
5. 지커 인텔리전트 테크놀러지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)의 주식은 29.31% 상승했다. 여러 미국 상장 중국 주식들이 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a> (약 983억 6천만 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지했다고 발표한 후 상승했다.
6. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 27.52% 상승했다.
7. 허크 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>)의 주식은 회사가 3분기 매출 실적이 예상보다 좋았고 2024 회계연도 장비 <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">임대 매출 성장 전망을 상향 조정</a>했다고 발표한 후 21.76% 상승했다.
8. 테라울프(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격 상승으로 18.59% 상승했다. 이 회사는 또한 4억 2,500만 달러를 전환사채로 조달할 것을 제안했다.
9. 아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">지오(Zio) AT 기기</a>의 이전 설계 변경과 관련된 510(k) 제출에 대해 FDA 승인을 받았다고 발표한 후 주가가 20.76% 상승했다.
10. 셀레스티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>)의 주식은 회사가 3분기 실적이 예상보다 좋았고 4분기 매출 가이던스를 예상치를 상회한다고 발표한 후 19.99% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
또한 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EB%89%B4%EC%9D%B8-%ED%8C%8C%EC%B8%A0-%EB%B0%8F-%ED%83%91%EB%B9%8C%EB%93%9C%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10/" target="_blank" rel="noopener">제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

PureCycle Technologies

뉴스

에 대한 최신 뉴스 PureCycle Technologies (NASDAQ:PCT) 주식

월요일, 10월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌